22.04.2018 Fresenius Medical Care AG & Co. KGaA  DE0005785802

DGAP-Adhoc: Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target


 
DGAP-Ad-hoc: Fresenius Medical Care AG & Co. KGaA / Key word(s): Change in Forecast Fresenius Medical Care AG & Co. KGaA adjusts its 2018 revenue growth target and confirms its net income growth target 22-Apr-2018 / 16:52 CET/CEST Disclosure of an inside information acc. to Article 17 MAR of the Regulation (EU) No 596/2014, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement. --------------------------------------------------------------------------- Fresenius Medical Care, the world's largest provider of dialysis products and services, has decided to adjust its 2018 revenue growth target from around 8 percent to a range of 5 to 7 percent at constant currency [1]. The main reason for this adjustment is the Company's recent reassessment of dosing of calcimimetic drugs in its dialysis service business in the United States. The reduction in dosing was faster than assumed and results in a lower than expected revenue contribution. At the same time, Fresenius Medical Care reconfirms its 2018 net income growth target of 13 to 15 percent at constant currency. The Company's 2018 targets continue to exclude the effects of the planned acquisition of NxStage Medical, Inc. and exclude the effects of the divestiture of Sound Inpatient Physicians Holdings, LLC. Final financial results for the first quarter 2018 will be published, as scheduled, on 3 May 2018. _____________ [1] 2017 adjusted for the effect of IFRS 15 implementation Fresenius Medical Care is the world's largest provider of products and services for individuals with renal diseases of which around 3.2 million patients worldwide regularly undergo dialysis treatment. Through its network of 3,752 dialysis clinics, Fresenius Medical Care provides dialysis treatments for 320,960 patients around the globe. Fresenius Medical Care is also the leading provider of dialysis products such as dialysis machines or dialyzers. Along with the core business, the company focuses on expanding the range of related medical services in the field of Care Coordination. Fresenius Medical Care is listed on the Frankfurt Stock Exchange (FME) and on the New York Stock Exchange (FMS). For more information visit the Company's website at www.freseniusmedicalcare.com. --------------------------------------------------------------------------- 22-Apr-2018 CET/CEST The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de --------------------------------------------------------------------------- Language: English Company: Fresenius Medical Care AG & Co. KGaA Else-Kröner-Straße 1 61352 Bad Homburg Germany Phone: +49 (0) 6172- 609 2525 Fax: +49 (0) 6172- 609 2301 E-mail: [email protected] Internet: www.freseniusmedicalcare.com ISIN: DE0005785802 WKN: 578580 Indices: DAX Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Hanover, Munich, Stuttgart, Tradegate Exchange; NYSE End of Announcement DGAP News Service --------------------------------------------------------------------------- 677311 22-Apr-2018 CET/CEST


Die wichtigsten Finanzdaten auf einen Blick
  2017 2018 2019 2020 2021 2022 2023e
Umsatzerlöse1 17.784,00 16.547,00 17.476,56 17.859,06 17.618,69 19.398,02 19.453,62
EBITDA1,2 3.098,00 3.763,00 3.862,72 4.090,31 3.475,97 3.350,00 3.121,41
EBITDA-Marge3 17,42 22,74 22,10 22,90 19,73 17,27
EBIT1,4 2.362,00 3.038,00 2.269,56 2.304,41 1.852,29 1.511,76 1.369,44
EBIT-Marge5 13,28 18,36 12,99 12,90 10,51 7,79 7,04
Jahresüberschuss1 1.554,00 2.226,00 1.438,50 1.435,83 1.219,03 894,33 732,46
Netto-Marge6 8,74 13,45 8,23 8,04 6,92 4,61 3,77
Cashflow1,7 2.192,00 2.062,00 2.566,95 4.233,16 2.489,50 2.167,38 2.628,80
Ergebnis je Aktie8 4,17 6,47 3,96 3,96 3,31 2,30 1,70
Dividende8 1,06 1,17 1,20 1,34 1,35 1,12 0,96
Quelle: boersengefluester.de und Firmenangaben

  Geschäftsbericht 2023 - Kostenfrei herunterladen.  
1 in Mio. Euro; 2 EBITDA = Ergebnis vor Zinsen, Steuern und Abschreibungen; 3 EBITDA in Relation zum Umsatz; 4 EBIT = Ergebnis vor Zinsen und Steuern; 5 EBIT in Relation zum Umsatz; 6 Jahresüberschuss (-fehlbetrag) in Relation zum Umsatz; 7 Cashflow aus der gewöhnlichen Geschäftstätigkeit; 8 in Euro; Quelle: boersengefluester.de

Wirtschaftsprüfer: PricewaterhouseCoopers

INVESTOR-INFORMATIONEN
©boersengefluester.de
Fresenius Medical Care
WKN Kurs in € Einschätzung Börsenwert in Mio. €
578580 35,600 Halten 10.445,52
KGV 2025e KGV 10Y-Ø BGFL-Ratio Shiller-KGV
12,49 17,80 0,69 10,03
KBV KCV KUV EV/EBITDA
0,79 3,97 0,54 5,64
Dividende '22 in € Dividende '23e in € Div.-Rendite '23e
in %
Hauptversammlung
1,12 1,19 3,34 16.05.2024
Q1-Zahlen Q2-Zahlen Q3-Zahlen Bilanz-PK
07.05.2024 30.07.2024 05.11.2024 22.03.2024
Abstand 60Tage-Linie Abstand 200Tage-Linie Performance YtD Performance 52 Wochen
-2,38% -9,23% -6,22% -7,00%
    
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu Fresenius Medical Care AG & Co. KGaA  ISIN: DE0005785802 können Sie bei EQS abrufen


Medtech , 578580 , FME , XETR:FME